Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: A randomised, double-blind, placebo-controlled phase 2 clinical trial

The Lancet

Volumn 381, Issue 9871, 2013, Pages 1037-1045

  Zhu, Feng Cai ^a   Liang, Zheng Lun ^b   Li, Xiu Ling ^c   Ge, Heng Ming ^d   Meng, Fan Yue ^a   Mao, Qun Ying ^b   Zhang, Yun Tao ^c   Hu, Yue Mei ^a   Zhang, Zhen Yu ^d   Li, Jing Xin ^a   Gao, Fan ^b   Chen, Qing Hua ^c   Zhu, Qi Yan ^d   Chu, Kai ^a   Wu, Xing ^b   Yao, Xin ^b   Guo, Hui Jie ^c   Chen, Xiao Qin ^d   Liu, Pei ^e   Dong, Yu Ying ^e   Li, Feng Xiang ^b   Shen, Xin Liang ^c   Wang, Jun Zhi ^b   more..

^a JIANGSU PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

^c Beijing Vigoo Biological ^*  (China)

^d Donghai County Center for Disease Control and Prevention   (China)

^e SOUTHEAST UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ENTEROVIRUS 71 VACCINE; PLACEBO; UNCLASSIFIED DRUG; VIRUS VACCINE;

ARTICLE; CHILD; CHINESE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; DRUG SAFETY; ENTEROVIRUS 71; ENTEROVIRUS INFECTION; FEMALE; HAND FOOT AND MOUTH DISEASE; HUMAN; IMMUNOGENICITY; INFANT; INFECTION PREVENTION; INJECTION SITE INDURATION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION;

EID: 84875382928     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61764-4     Document Type: Article

References (30)

1. Qiu J. Enterovirus 71 infection: a new threat to global public health? Lancet Neurol 2008; 7: 868-69.
2. AbuBakar S, Chan YF, Lam SK. Outbreaks of enterovirus 71 infection. N Engl J Med 2000; 342: 355-56.
3. Weng KF, Chen LL, Huang PN, Shih SR. Neural pathogenesis of enterovirus 71 infection. Microbes Infect 2010; 12: 505-10.
4. Bible JM, Pantelidis P, Chan PK, Tong CY. Genetic evolution of enterovirus 71: epidemiological and pathological implications. Rev Med Virol 2007; 17: 371-79.
5. Cordey S, Petty TJ, Schibler M, et al. Identification of site-specific adaptations conferring increased neural cell tropism during human enterovirus 71 infection. PLoS Pathog 2012; 8: e1002826.
6. Ho M, Chen ER, Hsu KH, et al, for the Taiwan Enterovirus Epidemic Working Group. An epidemic of enterovirus 71 infection in Taiwan. N Engl J Med 1999; 341: 929-35.
7. Mizuta K, Abiko C, Murata T, et al. Frequent importation of enterovirus 71 from surrounding countries into the local community of Yamagata, Japan, between 1998 and 2003. J Clin Microbiol 2005; 43: 6171-75.
8. Ma E, Lam T, Chan KC, Wong C, Chuang SK. Changing epidemiology of hand, foot, and mouth disease in Hong Kong, 2001-2009. Jpn J Infect Dis 2010; 63: 422-26.
9. Sarma N, Sarkar A, Mukherjee A, Ghosh A, Dhar S, Malakar R. Epidemic of hand, foot and mouth disease in West Bengal, India in August, 2007: a multicentric study. Indian J Dermatol 2009; 54: 26-30.
10. Chua KB, Kasri AR. Hand foot and mouth disease due to enterovirus 71 in Malaysia. Virol Sin 2011; 26: 221-28.
11. Liang Z, Mao Q, Gao Q, et al. Establishing China's national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines. Vaccine 2011; 29: 9668-74.
12. Mao Q, Li N, Yu X, et al. Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71. Arch Virol 2012; 157: 37-41.
13. Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 2010; 10: 778-90.
14. Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol 2010; 9: 1097-105.
15. Koroleva GA, Lukashev AN, Khudiakova LV, Mustafina AN, Lashkevich VA. Encephalomyelitis caused by enterovirus type 71 in children. Vopr Virusol 2010; 55: 4-10 (in Russian).
16. Huang WC, Huang LM, Kao CL, et al. Seroprevalence of enterovirus 71 and no evidence of crossprotection of enterovirus 71 antibody against the other enteroviruses in kindergarten children in Taipei city. J Microbiol Immunol Infect 2012; 45: 96-101.
17. WHO. A guide to clinical management and public health response for hand, foot and mouth disease (HFMD). Geneva, Switzerland: World Health Organization, 2011. http://www.wpro.who.int/publications/docs/ GuidancefortheclinicalmanagementofHFMD.pdf (accessed Sept 28, 2012).
18. Li YP, Liang ZL, Gao Q, et al. Safety and immunogenicity of a novel human enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, phase I clinical trial. Vaccine 2012; 30: 3295-303.
19. Meng F Y, Li JX, Li XL, et al. Tolerability and immunogenicity of an inactivated enterovirus 71 vaccine in Chinese healthy adults and children: an open label, phase 1 clinical trial. Hum Vaccin Immunother 2012; 8: 668-74.
20. Zhu FC, Wang JZ, Li XL, et al. Reactogenicity and immunogenicity of an enterovirus 71 vaccine in Chinese healthy children and infants. Pediatr Infect Dis J 2012; 31: 1158-65.
21. Deng C, Yang C, Wan J, Zhu L, Leng Q. Irregular poliovirus vaccination correlates to pulmonary edema of hand, foot, and mouth disease. Clin Vaccine Immunol 2011; 18: 1589-90.
22. Leng Q, Yang C, Zhu K, Deng C, Zhu L, Wan J. Pre-existing heterologous immunity to poliovirus vaccination may mitigate severity of hand, food and mouth disease caused by EV71. BMC Proc 2011; 5 (suppl 1): 27.
23. State Food and Drug Administration. The standard guidelines for adverse reactions grading of vaccine clinical trials, Oct 14, 2005 (in Chinese). http://www.sda.gov.cn/WS01/CL0844/9350-5.html (accessed Oct 5, 2012).
24. Mao Q-Y, Liao X-Y, Yu X, et al. Dynamic change of mother-source neutralizing antibodies against enterovirus 71 and coxsackievirus A16 in infants. Chin Med J (Engl) 2010; 123: 1679-84.
25. WHO. Polio laboratory manual, 4th edn, 2004. Geneva, Switzerland: World Health Organization, 2004. www.who.int/vaccines/en/poliolab/WHO-Polio-Manual-9. pdf (accessed Oct 5, 2012).
26. Asturias EJ, Dueger EL, Omer SB, et al. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants. J Infect Dis 2007; 196: 692-98.
27. Bonnet M-C, Dutta A. World wide experience with inactivated poliovirus vaccine. Vaccine 2008; 26: 4978-83.
28. WHO Weekly Epidemiological Record. Polio vaccines and polio immunization in the pre-eradication era: WHO position paper. Geneva, Switzerland: World Health Organization, 2010. http://www. who.int/wer/2010/wer8523/en/(accessed Oct 5, 2012).
29. Gossger N, Snape MD, Yu LM, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012; 307: 573-82.
30. Chen CW, Lee YP, Wang YF, Yu CK. Formaldehyde-inactivated human enterovirus 71 vaccine is compatible for co-immunization with a commercial pentavalent vaccine. Vaccine 2011; 29: 2772-76.